|
|
Vaccine Detail
|
Follicular lymphoma, patient-specific, soluble protein idiotype vaccine |
| Vaccine Information |
- Vaccine Name: Follicular lymphoma, patient-specific, soluble protein idiotype vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: Other
- Description: A patient-specific cancer vaccine directed against the soluble protein idiotype of an individual follicular lymphoma with potential antineoplastic activity. The vaccine may induce an idiotype-specific cytotoxic T-lymphocyte (CTL) response against follicular lymphoma cells expressing the idiotype, resulting in tumor cell lysis. (NCIT_C71036) Idiotypic vaccinations have the capacity of inducing an idiotype- and tumor-specific immune response, inducing specific immune responses able to kill in vivo follicular lymphoma cells, and prolonging survival of responding patients. This vaccine may contribute to preventing relapse indefinitely in responding patients. (NCT00530140)
|
| Host Response |
|
|
| References |
NCIT_C71036: Autologous Follicular Lymphoma-Derived Idiotype Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71036]
NCT00530140: Idiotypic Vaccination for Follicular Lymphoma Patients (FLIDVAX2006) [https://clinicaltrials.gov/study/NCT00530140]
|
|
